2019
Burden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy
Ambrosy AP, Stevens SR, Al‐Khalidi H, Rouleau JL, Bouabdallaoui N, Carson PE, Adlbrecht C, Cleland JGF, Dabrowski R, Golba KS, Pina IL, Sueta CA, Roy A, Sopko G, Bonow RO, Velazquez EJ, Investigators O. Burden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. European Journal Of Heart Failure 2019, 21: 373-381. PMID: 30698316, PMCID: PMC6818499, DOI: 10.1002/ejhf.1404.Peer-Reviewed Original ResearchConceptsCharlson co-morbidity indexCCI scoreSurgical revascularizationEjection fractionMedical therapySTICH trialHeart failureIschemic cardiomyopathyKansas City Cardiomyopathy QuestionnaireCo-morbidity indexCoronary artery bypassCo-morbid conditionsHealth-related qualityCoronary artery diseaseRisk of deathProportional hazards modelYears of ageTreatment effectsGreater functional limitationsArtery bypassCause mortalityIschemic etiologyArtery diseaseWalk testBaseline confounders
2014
Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction A VALIANT Study (Valsartan In Acute Myocardial Infarction)
Lewis EF, Li Y, Pfeffer MA, Solomon SD, Weinfurt KP, Velazquez EJ, Califf RM, Rouleau JL, Kober L, White HD, Schulman KA, Reed SD. Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction A VALIANT Study (Valsartan In Acute Myocardial Infarction). JACC Heart Failure 2014, 2: 159-165. PMID: 24720924, DOI: 10.1016/j.jchf.2013.12.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBundle-Branch BlockCaptoprilDeath, Sudden, CardiacDrug Therapy, CombinationFemaleHealth StatusHeart FailureHospitalizationHumansMaleMyocardial InfarctionQuality of LifeRecurrenceStrokeSurvivorsTetrazolesTreatment OutcomeValineValsartanConceptsNonfatal CV eventsEQ-5D assessmentCV eventsVisual analog scaleEQ-5D scoresCardiovascular eventsMyocardial infarctionEQ-5DBaseline EQ-5D scoresKillip class IINonfatal cardiovascular eventsHealth-related qualityLinear mixed-effects regression modelsQuality of lifeMixed effects regression modelsVALIANT studyWorse HRQLVAS scoresEjection fractionNonfatal eventsMI survivorsAnalog scaleVALIANT trialGeneric instrumentsPatients
2005
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, Investigators F. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American Heart Journal 2005, 150: 323-329. PMID: 16086938, DOI: 10.1016/j.ahj.2004.08.037.Peer-Reviewed Original ResearchMeSH KeywordsAmbulatory CareAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilDrug CostsGlobal HealthHealth Care CostsHealth ResourcesHeart FailureHospital CostsHospitalizationHumansMyocardial InfarctionProspective StudiesQuality of LifeTetrazolesValineValsartanVentricular Dysfunction, LeftConceptsQuality of lifeMyocardial infarctionAcute Myocardial Infarction trialLower medication costsMyocardial Infarction trialHealth-related qualityLinear mixed-effects regression analysisMultinational clinical trialsMixed-effects regression analysisCaptopril groupStudy medicationCardiovascular morbidityVentricular dysfunctionMost patientsHeart failureACE inhibitorsMedication costsProspective economic evaluationClinical trialsHigh riskPatientsValsartanResource useCaptoprilSignificant differences